Kirtikara K, Morham S G, Raghow R, Laulederkind S J, Kanekura T, Goorha S, Ballou L R
Department of Medicine, The University of Tennessee, Memphis, Tennessee 38163, USA.
J Exp Med. 1998 Feb 16;187(4):517-23. doi: 10.1084/jem.187.4.517.
Prostaglandin E2 (PGE2) production in immortalized, nontransformed cells derived from wild-type, cyclooxygenase 1-deficient (COX-1(-/-)) or cyclooxygenase 2-deficient (COX-2(-/-)) mice was examined after treatment with interleukin (IL)-1beta, tumor necrosis factor alpha, acidic fibroblast growth factor, and phorbol ester (phorbol myristate acetate). Compared with their wild-type counterparts, COX-1(-/-) or COX-2(-/-) cells exhibited substantially enhanced expression of the remaining functional COX gene. Furthermore, both basal and IL-1-induced expression of cytosolic phospholipase A2 (cPLA2), a key enzyme-regulating substrate mobilization for PGE2 biosynthesis, was also more pronounced in both COX-1(-/-) and COX-2(-/-) cells. Thus, COX-1(-/-) and COX-2(-/-) cells have the ability to coordinate the upregulation of the alternate COX isozyme as well as cPLA2 genes to overcome defects in prostaglandin biosynthetic machinery. The potential for cells to alter and thereby compensate for defects in the expression of specific genes such as COX has significant clinical implications given the central role of COX in a variety of disease processes and the widespread use of COX inhibitors as therapeutic agents.
在用白细胞介素(IL)-1β、肿瘤坏死因子α、酸性成纤维细胞生长因子和佛波酯(佛波醇肉豆蔻酸酯乙酸酯)处理后,检测了源自野生型、环氧化酶1缺陷(COX-1(-/-))或环氧化酶2缺陷(COX-2(-/-))小鼠的永生化、未转化细胞中前列腺素E2(PGE2)的产生情况。与野生型对应细胞相比,COX-1(-/-)或COX-2(-/-)细胞中剩余功能性COX基因的表达显著增强。此外,在COX-1(-/-)和COX-2(-/-)细胞中,作为调节PGE2生物合成底物动员的关键酶——胞质磷脂酶A2(cPLA2)的基础表达和IL-1诱导的表达也更明显。因此,COX-1(-/-)和COX-2(-/-)细胞有能力协调替代COX同工酶以及cPLA2基因的上调,以克服前列腺素生物合成机制中的缺陷。鉴于COX在多种疾病过程中的核心作用以及COX抑制剂作为治疗药物的广泛使用,细胞改变并从而补偿特定基因(如COX)表达缺陷的潜力具有重要的临床意义。